EFSA Journal (Oct 2021)

Maximum levels of cross‐contamination for 24 antimicrobial active substances in non‐target feed.
Part 10: Quinolones: flumequine and oxolinic acid

  • EFSA Panel on Biological Hazards (BIOHAZ),
  • Konstantinos Koutsoumanis,
  • Ana Allende,
  • Avelino Alvarez‐Ordóñez,
  • Declan Bolton,
  • Sara Bover‐Cid,
  • Marianne Chemaly,
  • Robert Davies,
  • Alessandra De Cesare,
  • Lieve Herman,
  • Friederike Hilbert,
  • Roland Lindqvist,
  • Maarten Nauta,
  • Giuseppe Ru,
  • Marion Simmons,
  • Panagiotis Skandamis,
  • Elisabetta Suffredini,
  • Dan I Andersson,
  • Vasileios Bampidis,
  • Johan Bengtsson‐Palme,
  • Damien Bouchard,
  • Aude Ferran,
  • Maryline Kouba,
  • Secundino López Puente,
  • Marta López‐Alonso,
  • Søren Saxmose Nielsen,
  • Alena Pechová,
  • Mariana Petkova,
  • Sebastien Girault,
  • Alessandro Broglia,
  • Beatriz Guerra,
  • Matteo Lorenzo Innocenti,
  • Ernesto Liébana,
  • Gloria López‐Gálvez,
  • Paola Manini,
  • Pietro Stella,
  • Luisa Peixe

DOI
https://doi.org/10.2903/j.efsa.2021.6862
Journal volume & issue
Vol. 19, no. 10
pp. n/a – n/a

Abstract

Read online

Abstract The specific concentrations of flumequine and oxolinic acid in non‐target feed for food‐producing animals, below which there would not be an effect on the emergence of, and/or selection for, resistance in bacteria relevant for human and animal health, as well as the specific antimicrobial concentrations in feed which have an effect in terms of growth promotion/increased yield were assessed by EFSA in collaboration with EMA. Details of the methodology used for this assessment, associated data gaps and uncertainties, are presented in a separate document. To address antimicrobial resistance, the Feed Antimicrobial Resistance Selection Concentration (FARSC) model developed specifically for the assessment was applied. However, due to the lack of data on the parameters required to calculate the FARSC, it was not possible to conclude the assessment until further experimental data are available. To address growth promotion, data from scientific publications obtained from an extensive literature review were used. No suitable data for the assessment were available. It was recommended to carry out studies to generate the data that are required to fill the gaps which prevented the calculation of the FARSC for these antimicrobials.

Keywords